-

Viz.ai to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced Chris Mansi, M.D., CEO and Co-Founder, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023 at 7:30am ET in New York, NY.

Dr. Mansi will share Viz.ai’s growth strategy, underpinned by its large and expanding hospital footprint and strong momentum in its life sciences business with collaborations with 7 of the 30 top global life science companies.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai Platform is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz.ai Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information, visit viz.ai.

Contacts

Ariane Lovell
ariane.lovell@finnpartners.com

Industry:

Viz.ai, Inc.

Release Versions
English
Hashtags
#ai
#aiinhealthcare
#carecoordination
#partnerships

Contacts

Ariane Lovell
ariane.lovell@finnpartners.com

Social Media Profiles
Viz.ai
Viz.ai
More News From Viz.ai, Inc.

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...

Viz.ai Launches Viz Assist: The First Multimodal AI Agent Platform for Faster Treatment and Better Outcomes

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz Assist™, a suite of autonomous AI agents that significantly enhance how care teams identify, prioritize, and act on critical patient data.1 Viz Assist marks a major step forward in Viz.ai’s mission to use technology to reduce time to treatment and improve patient outcomes. Viz Assist incorporates inputs from ambient listening and the electronic...

Viz.ai Launches Viz ACS™ to Accelerate Treatment for Heart Attack and Reduce Unnecessary Activations

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz ACS, a new solution in the Viz Cardio™ Suite. Designed to unite the acute coronary syndrome (ACS) care team on a single platform, Viz ACS provides Emergency Department (ED) physicians and cardiologists with the same high-quality ECGs and patient data in real time. This streamlined workflow can help improve communication, speeds treatment, and re...
Back to Newsroom